Last updated: 18 July 2019 at 8:52pm EST

Kathryn E Stein Net Worth




The estimated Net Worth of Kathryn E Stein is at least $346 mil dollars as of 7 January 2016. Kathryn Stein owns over 52,350 units of Macrogenics Inc stock worth over $345,909 and over the last 11 years Kathryn sold MGNX stock worth over $0.

Kathryn Stein MGNX stock SEC Form 4 insiders trading

Kathryn has made over 6 trades of the Macrogenics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Kathryn exercised 52,350 units of MGNX stock worth $45,021 on 7 January 2016.

The largest trade Kathryn's ever made was exercising 52,350 units of Macrogenics Inc stock on 7 January 2016 worth over $45,021. On average, Kathryn trades about 15,179 units every 74 days since 2013. As of 7 January 2016 Kathryn still owns at least 95,555 units of Macrogenics Inc stock.

You can see the complete history of Kathryn Stein stock trades at the bottom of the page.



What's Kathryn Stein's mailing address?

Kathryn's mailing address filed with the SEC is C/O MACROGENICS, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at Macrogenics Inc

Over the last 11 years, insiders at Macrogenics Inc have traded over $27,036,278 worth of Macrogenics Inc stock and bought 4,026,274 units worth $39,875,062 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Target N Vbb Biotech Ag Bio... y Edward Hurwitz. On average, Macrogenics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $132,068. The most recent stock trade was executed by Jay Philip Siegel on 20 May 2024, trading 4,500 units of MGNX stock currently worth $16,290.



What does Macrogenics Inc do?

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!



What does Macrogenics Inc's logo look like?

Macrogenics Inc logo

Complete history of Kathryn Stein stock trades at Macrogenics Inc

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
7 Jan 2016 Kathryn E Stein
Vicepresidente senior, Prd Dev y Reg Aff
Uso de opción 52,350 $0.86 $45,021
7 Jan 2016
95,555
22 Dec 2014 Kathryn E Stein
Vicepresidente senior, Prd Dev y Reg Aff
Uso de opción 10,946 $0.07 $766
22 Dec 2014
54,151
18 Dec 2014 Kathryn E Stein
Vicepresidente senior, Prd Dev y Reg Aff
Uso de opción 10,946 $0.71 $7,772
18 Dec 2014
54,151
21 Nov 2014 Kathryn E Stein
Vicepresidente senior, Prd Dev y Reg Aff
Uso de opción 10,946 $0.71 $7,772
21 Nov 2014
54,151
14 Nov 2014 Kathryn E Stein
Vicepresidente senior, Prd Dev y Reg Aff
Uso de opción 25,301 $0.94 $23,783
14 Nov 2014
45,295
29 May 2014 Kathryn E Stein
Vicepresidente senior, Prd Dev y Reg Aff
Uso de opción 10,946 $0.71 $7,772
29 May 2014
54,151


Macrogenics Inc executives and stock owners

Macrogenics Inc executives and other stock owners filed with the SEC include: